The modern role of corticosteroids in immune thrombotic thrombocytopenic purpura [0.03%]
现代皮质类固醇在免疫性血栓性血小板减少性紫癜中的作用
Konstantine Halkidis
Konstantine Halkidis
Deficiency of ADAMTS13 caused by autoantibodies leads to the thrombotic microangiopathy immune thrombotic thrombocytopenic purpura (iTTP). Corticosteroids have long been utilized in the management of patients with iTTP, both in the acute se...
Atypical hemolytic uremic syndrome: genetically-based insights into pathogenesis through an analysis of the complement regulator CD46 [0.03%]
非典型溶血性尿毒症综合症：通过分析补体调节器CD46得到的遗传学发病原理新认识
Xiaobo Wu,M Kathryn Liszewski,Anuja Java et al.
Xiaobo Wu et al.
The complement system is a critical innate immune defense mechanism that also facilitates antigen recognition as well as antibody production through the adaptive immune response. Overall, complement activation contributes to the immune syst...
Animal models for thrombotic thrombocytopenic purpura: a narrative review [0.03%]
血小板减少性紫癜动物模型的叙述性综述
Liang Zheng,X Long Zheng
Liang Zheng
Background and objective: Thrombotic thrombocytopenic purpura (TTP) is a potentially fatal blood disorder, resulting from severe deficiency of plasma ADAMTS13 (A Disintegrin And Metalloprotease with ThromboSpondin type 1 ...
Immune thrombotic thrombocytopenic purpura: pathogenesis and novel therapies: a narrative review [0.03%]
免疫性血栓性血小板减少性紫癜：发病机制和新型疗法：叙述性综述
Szumam Liu,X Long Zheng
Szumam Liu
Background and objectives: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, but potentially fatal blood disease, resulting from autoantibodies against A Disintegrin and Metalloprotease with ThromboSpondin Type...
The history of thrombotic thrombocytopenic purpura research: a narrative review [0.03%]
血小板减少性紫癜的研究历史：叙述性综述
Konstantine Halkidis,Bernhard Lämmle,X Long Zheng
Konstantine Halkidis
Background and objective: Thrombotic thrombocytopenic purpura (TTP) is a rare but debilitating thrombotic microangiopathy that results from severe deficiency of the enzyme ADAMTS13. The disorder was first described in the...
X Long Zheng
X Long Zheng
How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura? [0.03%]
caplacizumab在免疫性血栓性血小板减少性紫癜治疗中应如何使用？
Lucy Zheng,X Long Zheng
Lucy Zheng
Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody induction [0.03%]
输血引起的红细胞同种免疫和镰状细胞病：综述抗体产生机制
Jeanne E Hendrickson
Jeanne E Hendrickson
The high prevalence of red blood cell (RBC) alloantibodies in people with sickle cell disease (SCD) cannot be debated. Why people with SCD are so likely to form RBC alloantibodies, however, remains poorly understood. Over the past decade, a...
Sean X Gu,Sanjana Dayal
Sean X Gu
Andrea M Patterson,Louis M Pelus
Andrea M Patterson